Gamelin Erick 4
4 · Acrivon Therapeutics, Inc. · Filed May 20, 2026
Research Summary
AI-generated summary of this filing
Acrivon (ACRV) CDO Erick Gamelin Receives 38,584 RSU Award
What Happened Erick Gamelin, Chief Development Officer of Acrivon Therapeutics (ACRV), received a grant of 38,584 restricted stock units (RSUs) on May 18, 2026. The grant is reported at $0.00 per share (typical for RSU awards, which are compensation rather than a market purchase). These RSUs represent contingent rights to receive one share of Acrivon's common stock upon vesting.
Key Details
- Transaction type and date: Grant (Code A) on 2026-05-18; reported on Form 4 filed 2026-05-20.
- Shares/price: 38,584 RSUs granted at $0.00 (acquisition value $0).
- Vesting: 16.67% of the RSUs vest on November 18, 2026; the remainder vests in 10 substantially equal quarterly installments thereafter, subject to continuous service (footnote F1).
- Shares owned after transaction: Not specified in the filing.
- Timeliness: Filing was submitted two days after the grant (not indicated as late).
Context RSUs are compensation awards that convert to actual shares only as they vest; they are not an open‑market purchase or sale. Because this is a grant for service/retention, it does not by itself indicate the insider bought or sold stock in the open market.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-18+38,584→ 52,992 total
Footnotes (1)
- [F1]These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.